Evidence map›Paper›PMID 37946498›Full record

ArticleACS synthetic biology2023

MS2 Virus-like Particles as a Versatile Peptide Presentation Platform: Insights into the Deterministic Abilities for Accommodating Heterologous Peptide Lengths.

Mei Dang, Long J Wu, Si R Zhang, Jian R Zhu, Yu Z Hu, Chen X Yang, Xiao Y Zhang

Abstract read
In one paragraph

Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Chemical reviews · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mei DangQinba State Key Laboratory of Biological Resources and Ecological Environment, College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong, Shaanxi 723000, China.
Long J WuQinba State Key Laboratory of Biological Resources and Ecological Environment, College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong, Shaanxi 723000, China.
Si R ZhangXi'an Middle School of Shaanxi Province, Fengcheng Wulu 69, Weiyang, Xi'an 710006, China.
Jian R ZhuSchool of Pharmacy, Xi'an Jiaotong University, Xi'an 710049, China.
Yu Z HuQinba State Key Laboratory of Biological Resources and Ecological Environment, College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong, Shaanxi 723000, China.
Chen X YangQinba State Key Laboratory of Biological Resources and Ecological Environment, College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong, Shaanxi 723000, China.
Xiao Y ZhangQinba State Key Laboratory of Biological Resources and Ecological Environment, College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong, Shaanxi 723000, China.ORCID 0000-0002-0055-7322

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virus-like particles (VLPs) are nanostructures with the potential to present heterologous peptides at high density, thereby triggering heightened immunogenicity. RNA bacteriophage MS2 VLPs are a compelling delivery platform among them. However, a notable hurdle arises from the immune response toward MS2 coat protein, swiftly eliminating subsequent vaccinations via the same vector. Although larger inserts effectively mask carrier epitopes, current research predominantly focuses on displaying short conserved peptides (<30 aa). A systematic evaluation regarding the deterministic ability of MS2 VLPs as a platform for presenting heterologous peptides remains a gap. In light of this, we employed the "single-chain dimer" paradigm to scrutinize the tolerance of MS2 VLPs for peptide/protein insertions. The results unveiled functional MS2 VLP assembly solely for inserts smaller than 91 aa. Particularly noteworthy is the largest insertion achieved on the MS2 VLPs to date: the RNA helicase A (RHA) dsRNA-binding domains (dsRBD1). Attempts to introduce additional linkers or empty coat subunits fail to augment the expression level or assembly of the MS2 VLPs displaying dsRBD1, affirming 91 aa as the upper threshold for exogenous protein presentation. By illuminating the precise confines of MS2 VLPs in accommodating distinct peptide lengths, our study informs the selection of appropriate peptide and protein dimensions. This revelation not only underscores the scope of MS2 VLPs but also establishes a pivotal reference point, facilitating the strategic manipulation of MS2 VLPs to design next-generation epitope/antibody-based therapeutics.

Indexed as

Capsid ProteinsPeptidesEpitopesCapsid ProteinsEpitopesPeptidesMS2 VLPpeptide displayRNA helicase A (RHA) dsRNA-binding domain 1 (dsRBD1)virus-like particles (VLPs)

Identifiers

PMID37946498
PMCPMC10729756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.